Jen Jen Yeh MD
Endocrine, Melanoma, Pancreas, Surgical Oncology (Other than Breast)
Professor, Departments of Surgery and Pharmacology, University of North Carolina-Chapel Hill School of Medicine
Join to view full profile
101 Manning DrChapel Hill, NC 27599
Phone+1 919-966-8596
Fax+1 919-843-5515
Dr. Yeh is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2003 - 2005
Boston University Medical CenterResidency, Surgery, 1996 - 2003
Johns Hopkins University School of MedicineClass of 1996
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Publications & Presentations
PubMed
- Patient and Caregiver Perspectives on Surgical Informed Consent for Pancreaticoduodenectomy: An Applied Thematic Analysis.Mia MacDonald, Spencer Bock, Jen Jen Yeh, Kelsey Landrum
The Journal of Surgical Research. 2026-10-01 - Limitations of GATA6 and CK5 as surrogate markers for molecular subtyping in pancreatic cancer.Jaewon J Lee, Mohammed Aldakkak, Saryn Doucette, Yusha Liu, Ian C McCabe
HPB. 2026-08-06 - 1 citationsHuman pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation.Xian Zhang, Wilfred Wong, Hyein S Cho, Dapeng Yang, Gary Dixon
Developmental Cell. 2026-06-10
Press Mentions
Rashid Awarded Grant to Develop AI Tool That Recommends Optimal Clinical Trials to Pancreatic Cancer PatientsSeptember 24th, 2024
Device Targets Hard-to-Treat Pancreatic CancerFebruary 24th, 2016
Device Hits Pancreatic Tumors Hard with Toxic Four-Drug Cocktail, Sparing the BodyFebruary 8th, 2016
Grant Support
- Targeted EGFR for basal subtype pancreatic cancerUNIV OF NORTH CAROLINA CHAPEL HILL2024–2029
- Targeted EGFR for basal subtype pancreatic cancerUNIV OF NORTH CAROLINA CHAPEL HILL2024–2029
- UNC Integrated Translational Oncology Program (UNC-iTOP)UNIV OF NORTH CAROLINA CHAPEL HILL2019–2029
- Selective Targeting of Pancreatic Cancer SPOREUNIV OF NORTH CAROLINA CHAPEL HILL2022–2027
- Selective Targeting of Pancreatic Cancer SPOREUNIV OF NORTH CAROLINA CHAPEL HILL2022–2027
Professional Memberships
- Member
- Member
- Member
- Member
- Member
External Links
- Researchhttps://unclineberger.org/yehlab
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: